Book a visit by calling or texting 720-987-2155 or messaging our team online.
Homocysteine alone is insufficient as a predictor of diabetes mellitus
May 27, 2026, 09:00 ET Phase 3 REIMAGINE 13 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination 1 Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment 2 New Ozempic and Wegovy data provide further evidence of semaglutide's strong cardiometabolic profile PLAINSBORO, NJ and BAGSVRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place in New Orleans, June 58, 2026
They are prescribed off-label by clinicians based on clinical judgment, existing research, and patient-specific factors
Whitening injections before and after results often show noticeable differences in skin tone and texture
Skin Health and Healing Your skin loves vitamin D3 just as much as your bones do
